STA Pharmaceutical to open new transition metal catalysis center
The center will allow STA to introduce transition metal catalyst-screening technology to their existing small molecule process development and manufacturing platform.
STA Pharmaceutical, a WuXi AppTec company, has announced plans to launch a new transition metal catalysis center at their integrated API process R&D and manufacturing site in Changzhou China. The new state-of-the-art facility will allow STA to carry out rapid screening of metal catalysts, ligands, bases, acids, chemical resolving reagents, and amide formation coupling reagents, etc. The screening kits will enable high-throughput screening of metal catalysts and ligands for C-C, C-N, C-O and C-S formation reactions, as well as many other types of reactions such as chemical resolution and amide formation. The technology allows the STA team to more rapidly find the optimal catalysts using a parallel interactive testing approach.
A team of scientists specialized in this technology are currently being trained in the company’s Shanghai R&D center, and, once the new center becomes fully operational in early November, will move to the Changzhou site.
Most read news
Topics
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Bood metabolites associated with coffee consumption may affect kidney disease risk - Researchers have identified several metabolites whose levels are altered by coffee consumption
Indicia Production acquires METIS Biotechnologies
PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome
Carl Zeiss Meditec AG continues its growth trend - Positive revenue and earnings trend – further growth in recurring revenue

A taste for plastic - Discovered for the first time: New deep-sea enzyme breaks down PET plastic
Dendrimer technology gets a grip on cell proteins, could improve cancer treatment

Casting off: Leaving autoimmune disease behind thanks to an innovative treatment - Research team makes decisive breakthrough
APEIRON Biologics announces financing round for the further development of the COVID-19 drug APN01 - Financing secures further clinical trials and the supply of material for the treatment of COVID-19 patients
NovogeneAIT Singapore and the Genome Institute of Singapore forge Public-Private Partnership - Establishing whole genome sequencing centre in Singapore
Gene that influences the ability to remember faces
Estación_de_Fotobiología_Playa_Unión
